Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gefitinib resistance in non-small cell lung cancer (NSCLC) is often driven by MET proto-oncogene amplification and c-Met overexpression.
• Licochalcone A (Lico A), a natural product, has demonstrated broad anti-tumor activities, but its role in overcoming gefitinib resistance in NSCLC was previously unknown.

Purpose of the Study:

• To investigate the efficacy of Licochalcone A in overcoming gefitinib resistance in NSCLC.
• To elucidate the underlying mechanisms of Lico A's action on c-Met signaling.

Main Methods:

• Utilized gefitinib-resistant NSCLC cell lines (HCC827 and PC-9).
• Assessed Lico A's effects on cell viability, colony formation, and in vivo tumorigenesis.
• Analyzed apoptosis induction and protein expression levels (cleaved PARP, cleaved caspase-3).
• Investigated the interaction between c-Met and c-Cbl, and its role in c-Met ubiquitination and degradation.

Main Results:

• Lico A significantly reduced cell viability and colony formation in gefitinib-resistant NSCLC cells.
• Lico A suppressed in vivo tumor growth and induced intrinsic apoptosis.
• Lico A promoted c-Met interaction with c-Cbl, enhancing c-Met ubiquitination and degradation.
• Depletion of c-Cbl diminished Lico A's inhibitory effects, confirming the mechanism.

Conclusions:

• Licochalcone A effectively overcomes gefitinib resistance in NSCLC by suppressing c-Met signaling through enhanced ubiquitination and degradation.
• Lico A demonstrates potential as an antitumor agent for treating NSCLC with c-Met-mediated gefitinib resistance.